Poniard Pharmaceuticals said Wednesday it will lay off more than half its work force and replace CEO Jerry McMahon. The company said it will cut staff by 57 percent, leaving 21 workers in an effort to cut costs and focus on its potential cancer drug picoplatin. The layoffs will ...

NEW YORK (Reuters Health) - Boys who are short due to underlying health problems are more likely than their female counterparts to be treated with growth hormone -- but the gap is not explained by a bias in doctors' recommendations for treatment, a new study suggests. Growth hormone therapy may be prescribed to children with short stature due to certain medical causes ...

Keryx Biopharmaceuticals Inc. said Wednesday it reached an agreement with regulators on the design of a late-stage study of its cancer drug candidate perifosine. The agreement makes it more likely the Food and Drug Administration will approve perifosine if it meets its goals in the clinical ...

WASHINGTON (Reuters) - Prostate cancer treatments that cut off the supply of male hormone raise cholesterol, worsen blood sugar and make men fatter and thus likely raise the risk of heart attack, too, doctors said on Monday. An advisory published in the American Heart Association's journal Circulation recommends that doctors keep a close eye on men they treat with so-called ...